Express Pharma

Lupin launches generic Vigamox Ophthalmic solution in the US

1

The product is being manufactured at the company’s Pithampur facility

Lupin has announced the launch of its Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5 per cent (base) having received an approval from the United States Food and Drug Administration (FDA) earlier. The launched product is from Lupin’s Pithampur manufacturing facility.

Lupin’s Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5 per cent (base), is an AT1 rated generic equivalent of Novartis Pharms Corp.’s Vigamox Ophthalmic solution. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the organisms.

Comments are closed.